

# CITATION REPORT

List of articles citing

The role of interleukin-1 beta in the pathogenesis of multiple myeloma

DOI: 10.1016/s0889-8588(05)70115-5  
Hematology/Oncology Clinics of North America, 1999,  
13, 1117-25.

**Source:** <https://exaly.com/paper-pdf/30826154/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
72	TREATMENT OF MYELOMA-RELATED COMPLICATIONS. 76-85		
71	Immunophenotypic aberrations, DNA content, and cell cycle analysis of plasma cells in patients with myeloma and monoclonal gammopathies. <i>Blood Cells, Molecules, and Diseases</i> , <b>2000</b> , 26, 634-45	2.1	27
70	Myeloma bone disease. <i>Seminars in Hematology</i> , <b>2001</b> , 38, 276-85	4	115
69	Biology of osteoclast activation in cancer. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 3562-71	2.2	240
68	Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients. <i>Cancer</i> , <b>2001</b> , 91, 1219-30	3.1	95
67	Potential therapeutic uses of interleukin 1 receptor antagonists in human diseases. <i>Annals of the Rheumatic Diseases</i> , <b>2002</b> , 61, 960-7	2.4	58
66	IL-1beta expression in IgM monoclonal gammopathy and its relationship to multiple myeloma. <i>Leukemia</i> , <b>2002</b> , 16, 382-5	10.7	25
65	Multiple myeloma. <i>Hematology American Society of Hematology Education Program</i> , <b>2002</b> , 2002, 214-40	3.1	54
64	Solitary plasmacytoma in the setting of Langerhans cell histiocytosis. <i>Hematology</i> , <b>2002</b> , 7, 253-8	2.2	3
63	Lymphoplasmacytoid lymphoma presenting as severe osteoporosis. <i>American Journal of Hematology</i> , <b>2002</b> , 70, 77-80	7.1	7
62	Intra-tumoral interleukin-6 down-regulation system and genetic mutations of tumor suppressor genes in colorectal carcinoma. <i>Cancer</i> , <b>2002</b> , 94, 1584-92	6.4	34
61	Novel therapeutic approaches for multiple myeloma. <i>Immunological Reviews</i> , <b>2003</b> , 194, 164-76	11.3	79
60	Monoclonal gammopathies of undetermined significance: a review. <i>Immunological Reviews</i> , <b>2003</b> , 194, 112-39	11.3	96
59	Monoclonal gammopathy of undetermined significance in atomic bomb survivors: incidence and transformation to multiple myeloma. <i>British Journal of Haematology</i> , <b>2003</b> , 121, 405-10	4.5	13
58	Reply to Dr Mehta. <i>Leukemia</i> , <b>2003</b> , 17, 2238-2238	10.7	15
57	Serum Levels of Leptin in Multiple Myeloma Patients and Its Relation to Angiogenic and Inflammatory Cytokines. <i>International Journal of Biological Markers</i> , <b>2004</b> , 19, 52-57	2.8	21
56	Mechanisms of bone metastasis. <i>New England Journal of Medicine</i> , <b>2004</b> , 350, 1655-64	59.2	1762

55	Serum proinflammatory mediators at different periods of therapy in patients with multiple myeloma. <i>Mediators of Inflammation</i> , <b>2005</b> , 2005, 171-4	4.3	24
54	Targeting signalling pathways for the treatment of multiple myeloma. <i>Expert Opinion on Therapeutic Targets</i> , <b>2005</b> , 9, 359-81	6.4	32
53	Monoclonal gammopathy of undetermined significance. <i>Clinical Lymphoma and Myeloma</i> , <b>2005</b> , 6, 102-14		38
52	Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. <i>Mayo Clinic Proceedings</i> , <b>2006</b> , 81, 1047-53	6.4	193
51	Genomic instability and tissue expression of angiogenic growth factors in sporadic colorectal cancer. <i>Surgery</i> , <b>2006</b> , 139, 305-11	3.6	9
50	Evidence-based recommendations for monitoring bone disease and the response to enzyme replacement therapy in Gaucher patients. <i>Current Medical Research and Opinion</i> , <b>2006</b> , 22, 1045-64	2.5	69
49	Identification of two groups of smoldering multiple myeloma patients who are either high or low producers of interleukin-1. <i>Journal of Interferon and Cytokine Research</i> , <b>2006</b> , 26, 83-95	3.5	36
48	Preclinical studies of novel targeted therapies. <i>Hematology/Oncology Clinics of North America</i> , <b>2007</b> , 21, 1071-91, viii-ix	3.1	17
47	Pathophysiology of multiple myeloma bone disease. <i>Hematology/Oncology Clinics of North America</i> , <b>2007</b> , 21, 1035-49, viii	3.1	36
46	Complications of multiple myeloma. <i>Hematology/Oncology Clinics of North America</i> , <b>2007</b> , 21, 1231-46, xi	3.1	55
45	The malignant clone and the bone-marrow environment. <i>Best Practice and Research in Clinical Haematology</i> , <b>2007</b> , 20, 597-612	4.2	69
44	Molecular characterization, recombinant expression and bioactivity analysis of the interleukin-1 beta from the yellowfin sea bream, <i>Acanthopagrus latus</i> (Houttuyn). <i>Fish and Shellfish Immunology</i> , <b>2008</b> , 24, 323-36	4.3	48
43	The incidental monoclonal protein: current approach to management of monoclonal gammopathy of undetermined significance (MGUS). <i>Blood Reviews</i> , <b>2009</b> , 23, 257-65	11.1	12
42	Thrombopoietic cytokine and P-selectin levels in patients with multiple myeloma undergoing autologous stem cell transplantation: decrease in posttransplantation P-selectin levels might predict the degree of maximum response. <i>Clinical Lymphoma and Myeloma</i> , <b>2009</b> , 9, 229-33		4
41	Targeting the pathogenic role of interleukin 1{beta} in the progression of smoldering/indolent myeloma to active disease. <i>Mayo Clinic Proceedings</i> , <b>2009</b> , 84, 105-7	6.4	21
40	Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. <i>Mayo Clinic Proceedings</i> , <b>2009</b> , 84, 114-22	6.4	211
39	Why not treat human cancer with interleukin-1 blockade?. <i>Cancer and Metastasis Reviews</i> , <b>2010</b> , 29, 317-29	3.6	216
38	Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. <i>Nature Medicine</i> , <b>2010</b> , 16, 483-9	50.5	247

37	Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer. <i>Molecular Medicine</i> , <b>2011</b> , 17, 333-52	6.2	125
36	Role of IL-1 beta in the development of human T(H)17 cells: lesson from NLPR3 mutated patients. <i>PLoS ONE</i> , <b>2011</b> , 6, e20014	3.7	88
35	Blocking interleukin-1 in acute and chronic autoinflammatory diseases. <i>Journal of Internal Medicine</i> , <b>2011</b> , 269, 16-28	10.8	103
34	A clinical perspective of IL-1 as the gatekeeper of inflammation. <i>European Journal of Immunology</i> , <b>2011</b> , 41, 1203-17	6.1	509
33	Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. <i>Nature Reviews Drug Discovery</i> , <b>2012</b> , 11, 633-52	64.1	1160
32	Adenosine regulates bone metabolism via A1, A2A, and A2B receptors in bone marrow cells from normal humans and patients with multiple myeloma. <i>FASEB Journal</i> , <b>2013</b> , 27, 3446-54	0.9	59
31	Treating inflammation by blocking interleukin-1 in humans. <i>Seminars in Immunology</i> , <b>2013</b> , 25, 469-84	10.7	348
30	Complications and Special Presentations of Plasma Cell Myeloma. <b>2013</b> , 665-680		1
29	Epidemiology of Multiple Myeloma. <b>2013</b> , 547-563		4
28	An expanding role for interleukin-1 blockade from gout to cancer. <i>Molecular Medicine</i> , <b>2014</b> , 20 Suppl 1, S43-58	6.2	66
27	Arsenic trioxide and other arsenical compounds inhibit the NLRP1, NLRP3, and NAIP5/NLRC4 inflammasomes. <i>Journal of Immunology</i> , <b>2014</b> , 192, 763-70	5.3	36
26	TPL2 kinase regulates the inflammatory milieu of the myeloma niche. <i>Blood</i> , <b>2014</b> , 123, 3305-15	2.2	68
25	A novel human anti-interleukin-1 neutralizing monoclonal antibody showing in vivo efficacy. <i>MAbs</i> , <b>2014</b> , 6, 765-73	6.6	42
24	Gaucher iPSC-derived macrophages produce elevated levels of inflammatory mediators and serve as a new platform for therapeutic development. <i>Stem Cells</i> , <b>2014</b> , 32, 2338-49	5.8	56
23	Immunomodulatory effects of the Agaricus blazei Murrill-based mushroom extract AndoSan in patients with multiple myeloma undergoing high dose chemotherapy and autologous stem cell transplantation: a randomized, double blinded clinical study. <i>BioMed Research International</i> , <b>2015</b> , 2015, 718539	3	33
22	Pulmonary hypertension complicating multiple myeloma. <i>Pulmonary Circulation</i> , <b>2015</b> , 5, 590-7	2.7	12
21	The evaluation of NT-proCNP, C-reactive protein and serum amyloid A protein concentration in patients with multiple myeloma undergoing stem cell transplantation. <i>Leukemia Research</i> , <b>2016</b> , 47, 123-27		1
20	Modulating Inflammatory Cytokines. <b>2016</b> , 151-171		0

19	Interleukins 1 and 6 as Main Mediators of Inflammation and Cancer. <i>Biochemistry (Moscow)</i> , <b>2016</b> , 81, 80-90	2.9	73
18	Treatment of Inflammatory Diseases with IL-1 Blockade. <i>Current Otorhinolaryngology Reports</i> , <b>2018</b> , 6, 1-14	0.5	5
17	Overview of the IL-1 family in innate inflammation and acquired immunity. <i>Immunological Reviews</i> , <b>2018</b> , 281, 8-27	11.3	603
16	Inflammasome inhibitors: promising therapeutic approaches against cancer. <i>Journal of Hematology and Oncology</i> , <b>2019</b> , 12, 64	22.4	40
15	The emerging roles of inflammasome-dependent cytokines in cancer development. <i>EMBO Reports</i> , <b>2019</b> , 20,	6.5	43
14	Interleukin-1 Mediated Autoinflammation From Heart Disease to Cancer. <b>2019</b> , 711-725		1
13	Emicroglobulin triggers NLRP3 inflammasome activation in tumor-associated macrophages to promote multiple myeloma progression. <i>Immunity</i> , <b>2021</b> , 54, 1772-1787.e9	32.3	8
12	Inhibitors of histone deacetylases as anti-inflammatory drugs. <i>Ernst Schering Research Foundation Workshop</i> , <b>2006</b> , 45-60		15
11	MIP-1 alpha and myeloma bone disease. <i>Cancer Treatment and Research</i> , <b>2004</b> , 118, 83-100	3.5	34
10	Solitary Plasmacytoma of Bone and Extramedullary Plasmacytoma. <b>2004</b> , 111-118		1
9	Interleukin-1βs a potential therapeutic target for periodontitis: a narrative review. <i>International Journal of Oral Science</i> , <b>2020</b> , 12, 2	27.9	68
8	Increased osteoclastogenesis in mice lacking the carcinoembryonic antigen-related cell adhesion molecule 1. <i>PLoS ONE</i> , <b>2014</b> , 9, e114360	3.7	1
7	Niches Within the Multiple Myeloma Bone Marrow Microenvironment. <i>Translational Medicine Series</i> , <b>2007</b> , 61-74		1
6	Microenvironment Factors Influencing Skeletal Metastases. 135-160		
5	Monoclonal Gammopathies of Undetermined Significance and Smoldering Multiple Myeloma. <b>2014</b> , 65-80		
4	Established and novel methods for treating inflammatory diseases by inhibition of cytokines. 278-289		
3	Chemoprevention. <b>2005</b> , 519-528		
2	Cytokines in Multiple Myeloma. <b>2007</b> , 181-197		

1 Interleukin-1 receptor antagonist: From synthesis to therapeutic applications. **2023**, 47, 809-823

o